Unapproved Longevity Gene Therapy Bypasses FDA via Overseas Clinics
A US company is set to offer an unapproved gene therapy targeting the anti-ageing protein klotho through overseas clinics, according to reports. The therapy instructs cells to produce more klotho, a protein associated with longevity and cellular health.
By operating outside US borders, the company aims to bypass FDA regulations